Literature DB >> 19965633

Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells.

Katia Basso1, Masumichi Saito, Pavel Sumazin, Adam A Margolin, Kai Wang, Wei-Keat Lim, Yukiko Kitagawa, Christof Schneider, Mariano J Alvarez, Andrea Califano, Riccardo Dalla-Favera.   

Abstract

BCL6 is a transcriptional repressor required for mature B-cell germinal center (GC) formation and implicated in lymphomagenesis. BCL6's physiologic function is only partially known because the complete set of its targets in GC B cells has not been identified. To address this issue, we used an integrated biochemical-computational-functional approach to identify BCL6 direct targets in normal GC B cells. This approach includes (1) identification of BCL6-bound promoters by genome-wide chromatin immunoprecipitation, (2) inference of transcriptional relationships by the use of a regulatory network reverse engineering approach (ARACNe), and (3) validation of physiologic relevance of the candidate targets down-regulated in GC B cells. Our approach demonstrated that a large set of promoters (> 4000) is physically bound by BCL6 but that only a fraction of them is repressed in GC B cells. This set of 1207 targets identifies several cellular functions directly controlled by BCL6 during GC development, including activation, survival, DNA-damage response, cell cycle arrest, cytokine signaling, Toll-like receptor signaling, and differentiation. These results define a broad role of BCL6 in preventing centroblasts from responding to signals leading to exit from the GC before they complete the phase of proliferative expansion and of antibody affinity maturation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965633      PMCID: PMC2817639          DOI: 10.1182/blood-2009-06-227017

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  66 in total

1.  Acetylation inactivates the transcriptional repressor BCL6.

Authors:  Oksana R Bereshchenko; Wei Gu; Riccardo Dalla-Favera
Journal:  Nat Genet       Date:  2002-10-28       Impact factor: 38.330

2.  53BP1, a mediator of the DNA damage checkpoint.

Authors:  Bin Wang; Shuhei Matsuoka; Phillip B Carpenter; Stephen J Elledge
Journal:  Science       Date:  2002-10-03       Impact factor: 47.728

3.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.

Authors:  Weimin Ci; Jose M Polo; Leandro Cerchietti; Rita Shaknovich; Ling Wang; Shao Ning Yang; Kenny Ye; Pedro Farinha; Douglas E Horsman; Randy D Gascoyne; Olivier Elemento; Ari Melnick
Journal:  Blood       Date:  2009-03-23       Impact factor: 22.113

4.  BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma.

Authors:  Masumichi Saito; Urban Novak; Erich Piovan; Katia Basso; Pavel Sumazin; Christof Schneider; Marta Crespo; Qiong Shen; Govind Bhagat; Andrea Califano; Amy Chadburn; Laura Pasqualucci; Riccardo Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-23       Impact factor: 11.205

5.  BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

Authors:  A L Shaffer; X Yu; Y He; J Boldrick; E P Chan; L M Staudt
Journal:  Immunity       Date:  2000-08       Impact factor: 31.745

6.  TGF-beta receptor controls B cell responsiveness and induction of IgA in vivo.

Authors:  B B Cazac; J Roes
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

7.  Human USP3 is a chromatin modifier required for S phase progression and genome stability.

Authors:  Francesco Nicassio; Nadia Corrado; Joseph H A Vissers; Liliana B Areces; Steven Bergink; Jurgen A Marteijn; Bart Geverts; Adriaan B Houtsmuller; Wim Vermeulen; Pier Paolo Di Fiore; Elisabetta Citterio
Journal:  Curr Biol       Date:  2007-11-01       Impact factor: 10.834

8.  Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells.

Authors:  Ryan T Phan; Masumichi Saito; Yukiko Kitagawa; Anthony R Means; Riccardo Dalla-Favera
Journal:  Nat Immunol       Date:  2007-09-09       Impact factor: 25.606

9.  The novel p53 target gene IRF2BP2 participates in cell survival during the p53 stress response.

Authors:  Max Koeppel; Simon J van Heeringen; Leonie Smeenk; Anna C Navis; Eva M Janssen-Megens; Marion Lohrum
Journal:  Nucleic Acids Res       Date:  2008-11-28       Impact factor: 16.971

10.  Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis.

Authors:  P Nagarajan; T M Onami; S Rajagopalan; S Kania; R Donnell; S Venkatachalam
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

View more
  112 in total

1.  Using systems and structure biology tools to dissect cellular phenotypes.

Authors:  Aris Floratos; Barry Honig; Dana Pe'er; Andrea Califano
Journal:  J Am Med Inform Assoc       Date:  2011-11-10       Impact factor: 4.497

Review 2.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

Review 3.  Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses.

Authors:  João Pedro Pereira; Lisa M Kelly; Jason G Cyster
Journal:  Int Immunol       Date:  2010-06       Impact factor: 4.823

4.  Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression.

Authors:  Brygida Bisikirska; Mukesh Bansal; Yao Shen; Julie Teruya-Feldstein; Raju Chaganti; Andrea Califano
Journal:  Cancer Res       Date:  2015-11-20       Impact factor: 12.701

5.  Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.

Authors:  Mingxing Teng; Scott B Ficarro; Hojong Yoon; Jianwei Che; Jing Zhou; Eric S Fischer; Jarrod A Marto; Tinghu Zhang; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2020-04-03       Impact factor: 4.345

6.  Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?

Authors:  Leandro Cerchietti; Ari Melnick
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

Review 7.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

8.  IL-21 and CD40L synergistically promote plasma cell differentiation through upregulation of Blimp-1 in human B cells.

Authors:  B Belinda Ding; Enguang Bi; Hongshan Chen; J Jessica Yu; B Hilda Ye
Journal:  J Immunol       Date:  2013-01-16       Impact factor: 5.422

9.  Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma.

Authors:  Weicheng Ren; Xiaofei Ye; Hong Su; Wei Li; Dongbing Liu; Mohammad Pirmoradian; Xianhuo Wang; Bo Zhang; Qiang Zhang; Longyun Chen; Man Nie; Yao Liu; Bin Meng; Huiqiang Huang; Wenqi Jiang; Yixin Zeng; Wenyu Li; Kui Wu; Yong Hou; Klas G Wiman; Zhiming Li; Huilai Zhang; Roujun Peng; Shida Zhu; Qiang Pan-Hammarström
Journal:  Blood       Date:  2018-03-15       Impact factor: 22.113

Review 10.  Molecular pathology of lymphoma.

Authors:  S E Coupland
Journal:  Eye (Lond)       Date:  2012-12-07       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.